Hahn, Noah M.
Johns Hopkins University · Johns Hopkins Medicine
3 papers on CoChatORCID 0000-0002-1016-9024
Most cited papers
- Verified
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 869
- Verified
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Vuky, J., Balar, A. V., Castellano, D., O’Donnell, P. H., Grivas, P., Bellmunt, J., Powles, T., Bajorin, D., Hahn, N. M., Savage, M. J., et al. (2020) · Journal of Clinical Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 291
- Verified
Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research
Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations
Cited by 12
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free